erythromycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, produced by Streptomyces strains	1048	114-07-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: erythromycin gluceptate erythromycin lactobionate erythromycin stearate erythromycin Erythromycin A erythrocin erythromycin phosphate erythromycin thiocyanate	A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Molecular weight: 733.94 Formula: C37H67NO13 CLOGP: 1.63 LIPINSKI: 2 HAC: 14 HDO: 5 TPSA: 193.91 ALOGS: -3.20 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

erythromycin gluceptate
erythromycin lactobionate
erythromycin stearate
erythromycin
Erythromycin A
erythrocin
erythromycin phosphate
erythromycin thiocyanate

A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.

Molecular weight: 733.94
Formula: C37H67NO13
CLOGP: 1.63
LIPINSKI: 2
HAC: 14
HDO: 5
TPSA: 193.91
ALOGS: -3.20
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	g	O
2	g	O
1	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	2.10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	90.88 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	35 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.95 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.60 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.10 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
June 24, 1964	FDA	ARBOR PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	4895.38	11.96	2286	19960	272919	55996902
International normalised ratio fluctuation	240.38	11.96	72	22174	2342	56267479
Bloody discharge	178.03	11.96	51	22195	1414	56268407
Lyme disease	135.27	11.96	49	22197	2909	56266912
Seronegative arthritis	84.35	11.96	34	22212	2702	56267119
Exposure during pregnancy	67.19	11.96	159	22087	136183	56133638
Necrosis ischaemic	62.81	11.96	20	22226	799	56269022
Abortion spontaneous	59.93	11.96	80	22166	43673	56226148
Anaphylactic reaction	59.09	11.96	93	22153	58902	56210919
Vomiting	54.13	11.96	359	21887	497869	55771952
Faecal volume decreased	50.72	11.96	12	22234	152	56269669
Drug interaction	49.92	11.96	189	22057	209566	56060255
Beta haemolytic streptococcal infection	49.78	11.96	21	22225	1873	56267948
Pneumonia streptococcal	48.69	11.96	20	22226	1668	56268153
Wheezing	47.72	11.96	97	22149	74929	56194892
Amniotic cavity infection	47.68	11.96	18	22228	1200	56268621
Dislocation of vertebra	43.60	11.96	27	22219	5388	56264433
Pneumococcal infection	39.34	11.96	12	22234	415	56269406
Mass excision	38.49	11.96	11	22235	302	56269519
Ototoxicity	37.71	11.96	15	22231	1151	56268670
Umbilical erythema	36.30	11.96	8	22238	72	56269749
Completed suicide	36.15	11.96	5	22241	133828	56135993
Death	35.46	11.96	50	22196	341376	55928445
Pain	35.28	11.96	139	22107	663045	55606776
Vertigo positional	34.38	11.96	18	22228	2611	56267210
Drug intolerance	33.10	11.96	198	22048	264620	56005201
Purpura senile	32.81	11.96	11	22235	518	56269303
Rash	31.98	11.96	316	21930	492731	55777090
Spondylitis	31.26	11.96	18	22228	3147	56266674
Caesarean section	31.07	11.96	35	22211	16056	56253765
Therapeutic product effect incomplete	30.73	11.96	102	22144	105929	56163892
Stevens-Johnson syndrome	28.84	11.96	40	22206	22623	56247198
Tarsal tunnel syndrome	28.71	11.96	10	22236	529	56269292
Bronchial obstruction	28.70	11.96	13	22233	1375	56268446
Premature baby	27.65	11.96	36	22210	19169	56250652
Lip swelling	27.10	11.96	42	22204	26230	56243591
Infection	26.48	11.96	152	22094	200054	56069767
Serum sickness-like reaction	26.08	11.96	9	22237	463	56269358
Wound infection	25.91	11.96	31	22215	15162	56254659
Spinal fusion surgery	25.61	11.96	18	22228	4438	56265383
Premature rupture of membranes	24.52	11.96	18	22228	4747	56265074
Abdominal pain upper	23.33	11.96	135	22111	178178	56091643
Drug ineffective	23.27	11.96	242	22004	918747	55351074
Oligohydramnios	22.93	11.96	19	22227	5975	56263846
Drug tolerance decreased	22.27	11.96	27	22219	13384	56256437
Death neonatal	21.74	11.96	9	22237	765	56269056
Urticaria	21.23	11.96	113	22133	144563	56125258
Fall	20.86	11.96	72	22174	357438	55912383
Alopecia	20.78	11.96	54	22192	293404	55976417
Resorption bone increased	20.57	11.96	10	22236	1240	56268581
Mucous stools	20.22	11.96	14	22232	3370	56266451
Vestibular disorder	20.02	11.96	10	22236	1315	56268506
Pharyngeal oedema	19.28	11.96	25	22221	13260	56256561
Ergot poisoning	19.19	11.96	5	22241	96	56269725
Maternal drugs affecting foetus	19.19	11.96	16	22230	5077	56264744
Adjustment disorder with depressed mood	19.16	11.96	16	22230	5087	56264734
Corneal neovascularisation	18.59	11.96	5	22241	109	56269712
Corneal perforation	17.78	11.96	7	22239	523	56269298
Nasopharyngitis	17.76	11.96	38	22208	220921	56048900
Stenotrophomonas infection	17.24	11.96	10	22236	1771	56268050
Nodule	16.79	11.96	28	22218	18591	56251230
Ulcerative keratitis	16.68	11.96	11	22235	2444	56267377
Acute generalised exanthematous pustulosis	16.60	11.96	20	22226	9849	56259972
Pemphigus	16.31	11.96	23	22223	157189	56112632
Febrile neutropenia	16.07	11.96	11	22235	105534	56164287
Anal candidiasis	15.69	11.96	3	22243	12	56269809
Maternal exposure during pregnancy	15.55	11.96	128	22118	189425	56080396
Stomatitis	15.40	11.96	15	22231	120795	56149026
Starvation ketoacidosis	15.30	11.96	4	22242	78	56269743
Systemic lupus erythematosus	15.29	11.96	30	22216	180048	56089773
Infantile haemangioma	14.93	11.96	4	22242	86	56269735
Interstitial lung disease	14.86	11.96	53	22193	57010	56212811
Benign laryngeal neoplasm	14.68	11.96	3	22243	18	56269803
Toxicity to various agents	14.64	11.96	43	22203	224521	56045300
Breast cancer stage III	14.55	11.96	16	22230	7147	56262674
Cardiac arrest neonatal	14.47	11.96	4	22242	97	56269724
Synovitis	14.46	11.96	26	22220	161279	56108542
Corneal deposits	13.98	11.96	5	22241	286	56269535
Dysphoria	13.82	11.96	13	22233	4829	56264992
Premature delivery	13.78	11.96	32	22214	27028	56242793
Jarisch-Herxheimer reaction	13.51	11.96	5	22241	315	56269506
Product packaging issue	13.43	11.96	7	22239	1006	56268815
Bronchitis	13.37	11.96	83	22163	112228	56157593
Anaemia	12.95	11.96	58	22188	267453	56002368
Stillbirth	12.83	11.96	14	22232	6200	56263621
Pseudomembranous colitis	12.80	11.96	10	22236	2893	56266928
Renal impairment neonatal	12.68	11.96	3	22243	38	56269783
Keratitis	12.61	11.96	10	22236	2957	56266864
Campylobacter gastroenteritis	12.56	11.96	5	22241	384	56269437
Walking aid user	12.42	11.96	16	22230	8427	56261394
Blepharitis	12.27	11.96	9	22237	2371	56267450
Infusion related reaction	12.22	11.96	42	22204	208889	56060932
Abdominal pain	12.20	11.96	156	22090	258649	56011172
Malignant neoplasm progression	12.12	11.96	7	22239	73580	56196241

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	485.04	14.64	284	8730	72315	31616015
Toxic epidermal necrolysis	76.81	14.64	55	8959	19469	31668861
Hyphaema	72.72	14.64	19	8995	521	31687809
Drug interaction	64.81	14.64	166	8848	208377	31479953
Product packaging issue	61.67	14.64	17	8997	574	31687756
Premature baby	49.37	14.64	41	8973	18025	31670305
Rhabdomyolysis	42.99	14.64	70	8944	63511	31624819
Dystonia	42.96	14.64	30	8984	10195	31678135
Stupor	39.04	14.64	18	8996	2766	31685564
Obstruction gastric	34.54	14.64	12	9002	880	31687450
Coagulation time prolonged	34.18	14.64	13	9001	1235	31687095
Acute generalised exanthematous pustulosis	33.31	14.64	21	8993	6019	31682311
Intraocular pressure increased	31.05	14.64	19	8995	5168	31683162
Foetal death	30.77	14.64	8	9006	215	31688115
Eye pain	29.67	14.64	26	8988	12278	31676052
Deafness bilateral	29.15	14.64	11	9003	1022	31687308
Brain oedema	28.73	14.64	26	8988	12806	31675524
Pyloric stenosis	28.46	14.64	10	9004	758	31687572
Low birth weight baby	28.23	14.64	20	8994	6950	31681380
Impaired gastric emptying	27.76	14.64	15	8999	3229	31685101
Foetal exposure during pregnancy	27.60	14.64	45	8969	40831	31647499
Clonal haematopoiesis	27.47	14.64	6	9008	74	31688256
Product dispensing error	26.67	14.64	18	8996	5786	31682544
Foetal arrhythmia	25.91	14.64	6	9008	98	31688232
Caesarean section	25.54	14.64	12	9002	1924	31686406
Cellulitis enterococcal	25.41	14.64	6	9008	107	31688223
SAPHO syndrome	25.15	14.64	6	9008	112	31688218
Oligohydramnios	23.12	14.64	7	9007	331	31687999
Onychophagia	22.72	14.64	5	9009	64	31688266
Maternal drugs affecting foetus	22.61	14.64	14	9000	3889	31684441
Pneumonia mycoplasmal	22.53	14.64	8	9006	626	31687704
Oculogyric crisis	22.27	14.64	10	9004	1445	31686885
Febrile neutropenia	22.07	14.64	4	9010	121845	31566485
Learning disorder	21.91	14.64	9	9005	1047	31687283
Tricuspid valve disease	21.53	14.64	6	9008	211	31688119
Ototoxicity	20.46	14.64	10	9004	1748	31686582
Respiratory acidosis	20.33	14.64	14	9000	4648	31683682
Sepsis neonatal	20.25	14.64	6	9008	263	31688067
Myasthenia gravis crisis	19.87	14.64	7	9007	535	31687795
Vasculitic rash	19.80	14.64	8	9006	892	31687438
Torsade de pointes	19.65	14.64	16	8998	6834	31681496
Hepatic necrosis	18.38	14.64	12	9002	3651	31684679
Potentiating drug interaction	18.29	14.64	13	9001	4540	31683790
Ischaemic hepatitis	18.28	14.64	9	9005	1598	31686732
Pathogen resistance	18.25	14.64	17	8997	8684	31679646
Swelling face	17.87	14.64	26	8988	21364	31666966
Myoglobinuria	17.81	14.64	7	9007	726	31687604
Accidental exposure to product	17.72	14.64	19	8995	11476	31676854
Cardio-respiratory arrest neonatal	17.34	14.64	3	9011	9	31688321
Neonatal disorder	17.17	14.64	7	9007	799	31687531
Folliculitis	17.02	14.64	12	9002	4136	31684194
Hepatic failure	16.87	14.64	32	8982	32670	31655660
Measles	16.73	14.64	5	9009	226	31688104
Exposure during pregnancy	16.51	14.64	16	8998	8582	31679748
Proteus infection	16.13	14.64	7	9007	933	31687397
Stevens-Johnson syndrome	15.82	14.64	22	8992	17350	31670980
Brain herniation	15.67	14.64	11	9003	3766	31684564
Megacolon	15.20	14.64	8	9006	1634	31686696
Pupillary disorder	15.05	14.64	5	9009	320	31688010
Visual acuity reduced	14.83	14.64	20	8994	15323	31673007
Mycoplasma infection	14.71	14.64	5	9009	343	31687987

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	3384.25	11.89	1704	23628	260755	70642357
International normalised ratio fluctuation	231.27	11.89	73	25259	3146	70899966
Bloody discharge	179.08	11.89	52	25280	1681	70901431
Lyme disease	141.24	11.89	49	25283	2840	70900272
Drug interaction	104.35	11.89	336	24996	381105	70522007
Product packaging issue	76.65	11.89	24	25308	1006	70902106
Seronegative arthritis	67.62	11.89	30	25302	3349	70899763
Toxic epidermal necrolysis	64.40	11.89	75	25257	39482	70863630
Necrosis ischaemic	60.79	11.89	20	25312	984	70902128
Hyphaema	60.51	11.89	19	25313	804	70902308
Beta haemolytic streptococcal infection	51.06	11.89	21	25311	1946	70901166
Pneumonia streptococcal	49.54	11.89	22	25310	2461	70900651
Ototoxicity	49.05	11.89	23	25309	2918	70900194
Dislocation of vertebra	45.92	11.89	26	25306	4874	70898238
Exposure during pregnancy	45.18	11.89	98	25234	87619	70815493
Anaphylactic reaction	44.75	11.89	89	25243	74885	70828227
Maternal exposure during pregnancy	44.36	11.89	115	25217	115230	70787882
Stevens-Johnson syndrome	43.91	11.89	59	25273	35848	70867264
Wheezing	43.78	11.89	101	25231	94069	70809043
Drug abuse	38.33	11.89	4	25328	147252	70755860
Abortion spontaneous	37.85	11.89	47	25285	26432	70876680
Drug intolerance	36.88	11.89	169	25163	225518	70677594
Febrile neutropenia	35.93	11.89	14	25318	204304	70698808
Pneumococcal infection	35.62	11.89	13	25319	873	70902239
Acute generalised exanthematous pustulosis	35.29	11.89	35	25297	15362	70887750
Mass excision	34.26	11.89	10	25322	329	70902783
Death	34.12	11.89	83	25249	509978	70393134
Completed suicide	33.19	11.89	20	25312	227115	70675997
Infection	32.35	11.89	155	25177	210630	70692482
Stupor	32.05	11.89	23	25309	6486	70896626
Caesarean section	31.57	11.89	29	25303	11578	70891534
Vertigo positional	30.89	11.89	17	25315	3016	70900096
Tarsal tunnel syndrome	30.34	11.89	10	25322	495	70902617
Purpura senile	30.22	11.89	10	25322	501	70902611
Therapeutic product effect incomplete	29.43	11.89	102	25230	119780	70783332
Intraocular pressure increased	27.70	11.89	24	25308	8877	70894235
Drug tolerance decreased	27.59	11.89	25	25307	9808	70893304
Lip swelling	27.38	11.89	46	25286	34008	70869104
Torsade de pointes	27.25	11.89	33	25299	18083	70885029
Coagulation time prolonged	27.09	11.89	14	25318	2190	70900922
Spinal fusion surgery	26.55	11.89	17	25315	3980	70899132
Rash	26.20	11.89	288	25044	510274	70392838
Vomiting	25.77	11.89	324	25008	592787	70310325
Learning disorder	25.54	11.89	9	25323	546	70902566
Deafness bilateral	25.46	11.89	13	25319	1983	70901129
Serum sickness-like reaction	25.28	11.89	9	25323	563	70902549
Wound infection	24.85	11.89	31	25301	17511	70885601
Respiratory acidosis	24.74	11.89	24	25308	10257	70892855
Oligohydramnios	24.59	11.89	15	25317	3225	70899887
Spondylitis	23.70	11.89	15	25317	3442	70899670
Product dispensing error	23.37	11.89	25	25307	11983	70891129
Adjustment disorder with depressed mood	23.30	11.89	16	25316	4207	70898905
Ergot poisoning	22.69	11.89	6	25326	136	70902976
Bronchial obstruction	22.57	11.89	13	25319	2517	70900595
Rhabdomyolysis	22.23	11.89	80	25252	95680	70807432
Corneal neovascularisation	22.06	11.89	6	25326	152	70902960
Premature rupture of membranes	22.05	11.89	15	25317	3883	70899229
Malignant neoplasm progression	21.96	11.89	8	25324	121731	70781381
Oculogyric crisis	21.79	11.89	13	25319	2685	70900427
Ulcerative keratitis	21.72	11.89	14	25318	3313	70899799
Anaemia	21.55	11.89	73	25259	403350	70499762
Pharyngeal oedema	21.06	11.89	27	25305	15669	70887443
Eye pain	20.96	11.89	41	25291	34061	70869051
Impaired gastric emptying	20.74	11.89	21	25311	9445	70893667
Resorption bone increased	20.56	11.89	10	25322	1375	70901737
SAPHO syndrome	20.01	11.89	6	25326	217	70902895
Fall	18.87	11.89	88	25244	444008	70459104
Swelling face	18.42	11.89	57	25275	63107	70840005
Dystonia	17.71	11.89	28	25304	19678	70883434
Haemoglobin decreased	17.43	11.89	29	25303	205130	70697982
Breast cancer stage III	16.84	11.89	16	25316	6665	70896447
Hypotension	16.66	11.89	81	25251	404300	70498812
Tricuspid valve disease	16.54	11.89	6	25326	396	70902716
Abdominal pain upper	16.47	11.89	122	25210	193480	70709632
Asthenia	15.93	11.89	97	25235	457569	70445543
Live birth	15.87	11.89	22	25310	13757	70889355
Urticaria	15.77	11.89	106	25226	162943	70740169
Vestibular disorder	15.74	11.89	10	25322	2310	70900802
Keratitis	15.64	11.89	12	25320	3745	70899367
Corneal deposits	15.63	11.89	6	25326	464	70902648
Amniotic cavity infection	15.57	11.89	7	25325	806	70902306
Anal candidiasis	15.28	11.89	3	25329	16	70903096
Benign laryngeal neoplasm	14.98	11.89	3	25329	18	70903094
Premature delivery	14.81	11.89	27	25305	21277	70881835
Neutropenia	14.78	11.89	45	25287	257111	70646001
Pneumonia mycoplasmal	14.57	11.89	8	25324	1413	70901699
Walking aid user	14.46	11.89	16	25316	7965	70895147
Bronchitis	14.35	11.89	81	25251	117162	70785950
Abdominal rigidity	14.29	11.89	10	25322	2711	70900401
Myasthenia gravis crisis	14.18	11.89	7	25325	994	70902118
Potentiating drug interaction	14.16	11.89	16	25316	8148	70894964
Myoglobinuria	13.96	11.89	7	25325	1028	70902084
Starvation ketoacidosis	13.66	11.89	4	25328	133	70902979
Cardiac arrest neonatal	13.63	11.89	3	25329	30	70903082
Pathogen resistance	13.53	11.89	20	25312	13259	70889853
Confusional state	13.50	11.89	54	25278	284344	70618768
Nodule	13.50	11.89	25	25307	19944	70883168
Maternal drugs affecting foetus	13.48	11.89	8	25324	1636	70901476
Corneal perforation	13.08	11.89	6	25326	724	70902388
Type 2 diabetes mellitus	13.05	11.89	40	25292	44040	70859072
Brain oedema	13.01	11.89	27	25305	23391	70879721
Pain	12.96	11.89	153	25179	628663	70274449
Dermatitis allergic	12.95	11.89	22	25310	16409	70886703
Toxicity to various agents	12.77	11.89	82	25250	382090	70521022
Platelet count decreased	12.68	11.89	28	25304	178194	70724918
Blood glucose increased	12.52	11.89	11	25321	102971	70800141
Ischaemic hepatitis	12.49	11.89	10	25322	3319	70899793
Clostridium colitis	12.48	11.89	9	25323	2557	70900555
Stomatitis	12.03	11.89	17	25315	128494	70774618
Documented hypersensitivity to administered product	12.02	11.89	6	25326	873	70902239
Nasopharyngitis	11.99	11.89	40	25292	222166	70680946
Vasculitic rash	11.95	11.89	8	25324	2018	70901094

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D10AF02	DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Antiinfectives for treatment of acne
ATC	D10AF52	DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Antiinfectives for treatment of acne
ATC	J01FA01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS Macrolides
ATC	S01AA17	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics
FDA CS	M0028311	Macrolides
FDA PE	N0000009982	Decreased Sebaceous Gland Activity
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011500	Protein Synthesis Inhibitors
FDA EPC	N0000175877	Macrolide
FDA EPC	N0000175935	Macrolide Antimicrobial

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute otitis media	indication	3110003
Listeriosis	indication	4241002	DOID:11573
Gonorrhea	indication	15628003	DOID:7551
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Acute gonococcal cervicitis	indication	20943002	DOID:10615
Pertussis	indication	27836007
Acute gonococcal urethritis	indication	29864006
Neonatal conjunctivitis	indication	34298002	DOID:9699
Gonorrhea of rectum	indication	42746002
Pneumonia due to Mycoplasma pneumoniae	indication	46970008
Bacterial pneumonia	indication	53084003	DOID:874
Acute gonococcal endometritis	indication	65295003	DOID:7527
Acute bacterial sinusitis	indication	75498004
Syphilis	indication	76272004
Pneumococcal pharyngitis	indication	76651006
Nongonococcal urethritis	indication	84619001
Acne vulgaris	indication	88616000
Urethritis due to Chlamydia trachomatis	indication	179101003
Chlamydial conjunctivitis	indication	231861005	DOID:13800
Pneumococcal pneumonia	indication	233607000
Chlamydial pneumonia	indication	233609002
Neonatal pneumonia	indication	233619008
Erythrasma	indication	238418005	DOID:4131
Streptococcus pyogenes infection	indication	302809008
Infective otitis media	indication	312218008
Diphtheria	indication	397428000
Infection due to Staphylococcus aureus	indication	406602003
Recurrent Persistent Urethritis	indication
Superficial Ocular Infection	indication
Preoperative Bowel Preparation	indication
Prevention of Bacterial Endocarditis	indication
Chlamydia Cervicitis	indication
Rectal Chlamydia Trachomatis Infection	indication
Prevention of Neonatal Ophthalmia	indication
Pneumococcal Acute Otitis Media	indication
Legionnaires' Disease	indication
Rheumatic Fever Prevention	indication
Haemophilus Influenzae Acute Otitis Media	indication
Trachoma	off-label use	2576002	DOID:11265
Inhalational anthrax	off-label use	11389007
Actinomycotic infection	off-label use	11817007	DOID:8478
Enteric campylobacteriosis	off-label use	18081009
Lyme disease	off-label use	23502006	DOID:11729
Granuloma inguinale	off-label use	28867007	DOID:9113
Sinusitis	off-label use	36971009
Erysipelas	off-label use	44653001	DOID:11330
Blepharoconjunctivitis	off-label use	68659002	DOID:2456
Cutaneous anthrax	off-label use	84980006	DOID:7426
Ecthyma	off-label use	85791004
Gastrointestinal anthrax	off-label use	111798006	DOID:13386
Bacterial conjunctivitis	off-label use	128350005	DOID:9700
Bacterial infection of skin	off-label use	128936008
Lymphogranuloma venereum	off-label use	186946009	DOID:13819
Gastroesophageal reflux disease	off-label use	235595009	DOID:8534
Gastroparesis	off-label use	235675006
Chancroid	off-label use	266143009	DOID:13778
Meibomianitis	off-label use	309779001
Infective blepharitis	off-label use	312219000
Bacterial keratitis	off-label use	314557000
Erysipeloid	off-label use	400105005
Anthrax	off-label use	409498004	DOID:7427
Relapsing fever	off-label use	420079008	DOID:13034
Gastroscopy Adjunct	off-label use
Listeria Monocytogenes Septicemia	off-label use
Ureaplasma Pneumonia	off-label use
Torsades de pointes	contraindication	31722008
Third trimester pregnancy	contraindication	41587001
Megaloblastic anemia due to folate deficiency	contraindication	85649008	DOID:14026
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Cholestatic hepatitis	contraindication	95556007
Anemia due to enzyme deficiency	contraindication	111577008
Prolonged QT interval	contraindication	111975006
Hearing disorder	contraindication	128540005
Liver function tests abnormal	contraindication	166603001
Disease of blood AND/OR blood-forming organ	contraindication	191124002	DOID:74
Disease of liver	contraindication	235856003	DOID:409
Pseudomembranous enterocolitis	contraindication	397683000
Erythroderma	contraindication	399992009
Porphyria	contraindication	418470004
Congenital long QT syndrome	contraindication	442917000
Inflammatory dermatosis	contraindication	703938007

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Bacterial pneumonia	Indication
Cats	Upper respiratory infections	Indication
Cats	Secondary infections associated with panleukopenia	Indication
Cats	Bacterial wound infections caused by Staphylococcus species	Indication
Cats	Bacterial wound infections caused by Streptococcus species	Indication
Cattle	Bovine respiratory disease (BRD) associated with Pasturella multiocida	Indication
Cattle	Mastitis caused by Staphylococcus aureus	Indication
Cattle	Mastitis caused by Streptococcus dysgalactiae	Indication
Cattle	Mastitis caused by Streptococcus dysgalactiae	Indication
Cattle	Mastitis caused by Streptococcus uberis	Indication
Chickens	Prevention and reduction of lesions and in lowering severity of chronic respiratory disease	Indication
Chickens	Prevention of infectious coryza	Indication
Chickens	Prevention of chronic respiratory disease during periods of stress	Indication
Chickens	Chronic respiratory disease caused by Mycoplasma gallisepticum	Indication
Chickens	Infectious coryza caused by Hemophilus gallinarum	Indication
Dogs	Bacterial pneumonia	Indication
Dogs	upper respiratory infections	Indication
Dogs	Endometritis and metritis	Indication
Dogs	Bacterial wound infections caused by Staphylococcus species	Indication
Dogs	Bacterial wound infections caused by Streptococcus species	Indication
Dogs	Bacterial wound infections caused by Corynebacterium species	Indication
Turkeys	Chronic respiratory disease during periods of stress	Indication
Turkeys	Prevention and reduction of lesions and in lowering severity of chronic respiratory disease	Indication
Turkeys	Control of blue comb (nonspecific infectious enteritis)	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Gallimycin-100P	Bimeda Animal Health Limited	1
Erythro - 100, 200, Gallimycin-100	Bimeda Animal Health Limited	1
Gallimycin PFC	Bimeda Animal Health Limited	1
Erythro-36 Dry, Gallimycin-36 Dry	Bimeda Animal Health Limited	1
Gallimycin-36 Sterile	Bimeda Animal Health Limited	1
Erythromast 36	Zoetis Inc.	1
Erythro-100 Injection	Bimeda Animal Health Limited	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.65	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
250MG	ERYTHROMYCIN	TORRENT	A211975	July 26, 2021	RX	TABLET, DELAYED RELEASE	ORAL	April 2, 2022	COMPETITIVE GENERIC THERAPY
500MG	ERYTHROMYCIN	TORRENT	A211975	July 26, 2021	RX	TABLET, DELAYED RELEASE	ORAL	April 2, 2022	COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN	IC50	7.41	CHEMBL
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN	IC50	4.82	WOMBAT-PK
Bile salt export pump	Transporter	O95342	ABCBB_HUMAN	IC50	5.39	CHEMBL
Motilin receptor	GPCR	O43193	MTLR_HUMAN	Ki	4.43	CHEMBL
Cytochrome P450 1B1	Enzyme	Q16678	CP1B1_HUMAN	IC50	4.40	CHEMBL

External reference:

ID	Source
4017594	VUID
N0000145975	NUI
D00140	KEGG_DRUG
23067-13-2	SECONDARY_CAS_RN
3847-29-8	SECONDARY_CAS_RN
643-22-1	SECONDARY_CAS_RN
4017591	VANDF
4017594	VANDF
4017595	VANDF
4017596	VANDF
C0014806	UMLSCUI
CHEBI:42355	CHEBI
ERY	PDB_CHEM_ID
CHEMBL2110577	ChEMBL_ID
CHEMBL1200506	ChEMBL_ID
CHEMBL532	ChEMBL_ID
CHEMBL3545060	ChEMBL_ID
CHEMBL1200510	ChEMBL_ID
D004917	MESH_DESCRIPTOR_UI
DB00199	DRUGBANK_ID
C010948	MESH_SUPPLEMENTAL_RECORD_UI
C011462	MESH_SUPPLEMENTAL_RECORD_UI
1456	IUPHAR_LIGAND_ID
C025000	MESH_SUPPLEMENTAL_RECORD_UI
39	INN_ID
63937KV33D	UNII
12560	PUBCHEM_CID
24346	RXNORM
33316	MMSL
3627	MMSL
4675	MMSL
4678	MMSL
4679	MMSL
4680	MMSL
4769	MMSL
4799	MMSL
72164	MMSL
d00046	MMSL
002755	NDDF
002758	NDDF
002759	NDDF
002760	NDDF
30427009	SNOMEDCT_US
372694001	SNOMEDCT_US
39152007	SNOMEDCT_US
698006	SNOMEDCT_US
83981000	SNOMEDCT_US
96032005	SNOMEDCT_US
96033000	SNOMEDCT_US
4501-00-2	SECONDARY_CAS_RN
7704-67-8	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5571	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5572	TABLET, FILM COATED	500 mg	ORAL	ANDA	23 sections
ERYGEL	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8075	GEL	20 mg	TOPICAL	NDA	18 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8212	GEL	20 mg	TOPICAL	NDA authorized generic	18 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	0404-7191	OINTMENT	5 mg	OPHTHALMIC	ANDA	18 sections
Erythrocin Lactobionate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-6476	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	13 sections
Erythrocin Lactobionate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-6476	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	13 sections
Erythrocin Lactobionate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-6482	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	NDA	13 sections
Erythrocin Lactobionate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-6482	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	NDA	13 sections
erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	0574-4024	OINTMENT	5 mg	OPHTHALMIC	ANDA	18 sections
Erythrocin Stearate	HUMAN PRESCRIPTION DRUG LABEL	1	10544-594	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Erythrocin Stearate	HUMAN PRESCRIPTION DRUG LABEL	1	10544-595	TABLET, FILM COATED	500 mg	ORAL	ANDA	23 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	13668-586	TABLET, DELAYED RELEASE	250 mg	ORAL	ANDA	25 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	13668-588	TABLET, DELAYED RELEASE	500 mg	ORAL	ANDA	25 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-606	TABLET, COATED	250 mg	ORAL	ANDA	14 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-606	TABLET, COATED	250 mg	ORAL	ANDA	14 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-607	TABLET, COATED	500 mg	ORAL	ANDA	14 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-607	TABLET, COATED	500 mg	ORAL	ANDA	14 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	13985-605	OINTMENT	5 mg	OPHTHALMIC	ANDA	18 sections
Erythromycin Lactobionate	HUMAN PRESCRIPTION DRUG LABEL	1	14789-116	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	24 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-088	CAPSULE, DELAYED RELEASE	250 mg	ORAL	ANDA	22 sections
ERY-TAB	HUMAN PRESCRIPTION DRUG LABEL	1	16590-089	TABLET, DELAYED RELEASE	333 mg	ORAL	ANDA	27 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-090	OINTMENT	5 mg	OPHTHALMIC	ANDA	9 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-091	TABLET, FILM COATED	250 mg	ORAL	ANDA	17 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	17478-070	OINTMENT	5 mg	OPHTHALMIC	ANDA	19 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	17478-070	OINTMENT	5 mg	OPHTHALMIC	ANDA	19 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	21695-173	OINTMENT	5 mg	OPHTHALMIC	ANDA	15 sections
ERYTHROMYCIN Base Filmtab	HUMAN PRESCRIPTION DRUG LABEL	1	21695-387	TABLET, FILM COATED	250 mg	ORAL	ANDA	24 sections
ERYTHROMYCIN Base Filmtab	HUMAN PRESCRIPTION DRUG LABEL	1	21695-389	TABLET, FILM COATED	500 mg	ORAL	ANDA	24 sections
ERY-TAB	HUMAN PRESCRIPTION DRUG LABEL	1	21695-457	TABLET, DELAYED RELEASE	333 mg	ORAL	ANDA	23 sections